Home › Endometrial Cancer
Endometrial Cancer clinical trials recruiting in the U.S.
168 studies for Endometrial Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX68 studies
- New York City, NY52 studies
- Boston, MA50 studies
- Arlington, VA39 studies
- Nashville, TN38 studies
- Los Angeles, CA34 studies
- St. Louis, MO29 studies
- Philadelphia, PA28 studies
- San Antonio, TX27 studies
- Queens, NY25 studies
- Columbus, OH25 studies
- Chicago, IL25 studies
- Oklahoma City, OK25 studies
- Dallas, TX24 studies
- Portland, OR24 studies
- Pittsburgh, PA23 studies
- Detroit, MI21 studies
- Cleveland, OH20 studies
- Rochester, MN20 studies
- Edison, NJ19 studies
- Washington, DC18 studies
- Minneapolis, MN18 studies
- Grand Rapids, MI18 studies
- Orlando, FL17 studies
- Atlanta, GA17 studies
- Seattle, WA17 studies
- Baldwin Park, CA17 studies
- Durham, NC16 studies
- Miami, FL16 studies
- Birmingham, AL16 studies
- San Diego, CA16 studies
- Denver, CO15 studies
- Austin, TX15 studies
- Tampa, FL15 studies
- Sarasota, FL15 studies
- Providence, RI14 studies
- New Haven, CT14 studies
- Salt Lake City, UT14 studies
- Indianapolis, IN14 studies
- San Francisco, CA14 studies
By state
- Alabama19 studies
- Alaska4 studies
- Arizona22 studies
- Arkansas12 studies
- California73 studies
- Colorado30 studies
- Connecticut20 studies
- Delaware4 studies
- District of Columbia10 studies
- Florida65 studies
- Georgia24 studies
- Hawaii3 studies
- Idaho4 studies
- Illinois38 studies
- Indiana19 studies
- Iowa10 studies
- Kansas5 studies
- Kentucky10 studies
- Louisiana15 studies
- Maine7 studies
- Maryland22 studies
- Massachusetts53 studies
- Michigan43 studies
- Minnesota39 studies
- Mississippi5 studies
- Missouri31 studies
- Montana5 studies
- Nebraska10 studies
- Nevada8 studies
- New Jersey32 studies
- New Mexico13 studies
- New York69 studies
- North Carolina31 studies
- North Dakota6 studies
- Ohio50 studies
- Oklahoma28 studies
- Oregon27 studies
- Pennsylvania42 studies
- Rhode Island14 studies
- South Carolina9 studies
- South Dakota11 studies
- Tennessee41 studies
- Texas91 studies
- Utah25 studies
- Virginia51 studies
- Washington20 studies
- West Virginia4 studies
- Wisconsin24 studies
Recently updated studies
Tirzepatide in Obesity-Driven Endometrial Cancer
RecruitingEarly phase 1
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07065552Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RecruitingPhase 1
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT05950464The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
Recruiting
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07059884A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07286331A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074A Phase 1 Study of the Safety and Tolerability of CTX-10726
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07419841Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Oct 2, 2026 · NCT01174121A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06586957A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07189871The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07285044A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07814248Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
RecruitingObservational study
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05051722Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601Study of AVZO-021 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251DESTINY-PANTUMOUR04
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
Recruiting
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT07270666Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT03564340Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT07594015A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT04590326From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.